Sentry Investment Management LLC Has $168,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Sentry Investment Management LLC cut its position in Edwards Lifesciences Co. (NYSE:EW) by 14.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,276 shares of the medical research company’s stock after selling 371 shares during the period. Sentry Investment Management LLC’s holdings in Edwards Lifesciences were worth $168,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. State Street Corp grew its holdings in shares of Edwards Lifesciences by 1.0% during the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after buying an additional 256,538 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Edwards Lifesciences by 2.2% during the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after acquiring an additional 284,918 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Edwards Lifesciences by 9.8% during the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after acquiring an additional 806,705 shares in the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $555,939,000. 79.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. The trade was a 12.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock worth $2,002,829 over the last quarter. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $71.46 on Wednesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business’s 50 day simple moving average is $72.78 and its 200 day simple moving average is $70.18. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a market cap of $42.15 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 4.82 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

EW has been the subject of a number of analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Truist Financial reiterated a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.